Table 2.
Studies published concerning the relationship between diabetes and MR-ONJ. Where BP-ONJ refers to bisphosphonate-associated osteonecrosis of the jaws.
| Study | Country | No. of Patients | Prevalence of Diabetes (%) | p-Value | Average Age | Comment |
|---|---|---|---|---|---|---|
| Vidal-Real, 2015 [19] | Spain | 194 | 86.6 | 0.048 | 68.91 | only patients treated with zoledronic acid; comparison BP-ONJ and BP-Treatment |
| Khamaisi, 2007 [18] | Israel | 31 | 58 | 0.001 | 64.8 | comparison BP-ONJ and BP-Treatment |
| Bocanegra-Perez, 2012 [22] | Spain | 44 | 35 | not calculated | 64.2 | |
| Fede, 2013 [26] | Italy | 87 | 9.2 | not significant | 70.7 | osteoporotic non-cancer patients |
| Anavi-Lev, 2013 [20] | Israel | 52 | 41 * | 0.02 | 74.5 | comparison between iv and po BP-treatment; diabetes prevalence higher in po-group |
| Diniz-Freitas, 2012 [23] | Spain | 20 | 20 | not calculated | 71.2 | |
| Lazarovici, 2009 [24] | Israel | 101 | 16 | not calculated | 63.5 | |
| Watters, 2013 [21] | USA | 154 | 24 | 0.05 | 64 | only BP-ONJ-patients included, comparison between progressive disease and remission |
| Manfredi, 2011 [25] | Italy | 25 | 16 | not calculated | 70.4 | only patients with BP-treatment due to osteoporosis |
| Wilkinson, 2007 [29] | USA | 16073 | 6.40 | not significant | n/a | |
| Molcho, 2013 [27] | Israel | 46 | 37 | not significant | 66 | |
| present study, 2016 | Germany | 35 | 14.30 | not significant | 68.8 | |
| 30.29 | 67.91 |
* value recalculated.